Bone Biologics Financials
This page shows Bone Biologics (BBLGW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing dependence, rather than operating receipts, remains the primary engine supporting this loss-making business.
In FY2025, net loss of-$3.1M and operating cash flow of-$2.7M were relatively close, indicating that reported losses largely tracked current cash consumption. In FY2022, operating cash flow of-$3.6M against net loss of-$1.5M left a much wider gap, so non-cash or working-capital effects then played a larger role.
The company recorded financing cash flow of
FY2025's 0.1x debt-to-equity and 13.8x current ratio describe a liability-light structure: current assets were ample relative to current liabilities, while debt was not the main balance-sheet constraint. The current ratio rose from 3.3x in FY2022 to 13.8x in FY2025, but that accounting liquidity coexists with continuing operating cash outflows.
Financial Health Signals
Bone Biologics does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bone Biologics passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
Bone Biologics reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bone Biologics reported -$3.1M in net income in fiscal year 2025. This represents an increase of 24.4% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bone Biologics held $5.3M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Bone Biologics's ROE was -57.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 60.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Bone Biologics invested $1.1M in research and development in fiscal year 2025. This represents a decrease of 50.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BBLGW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $309K+118.0% | $142K | N/A | $188K-2.0% | $192K-54.8% | $424K | N/A | $430K |
| SG&A Expenses | $499K-24.7% | $663K | N/A | $527K-5.2% | $556K-9.5% | $615K | N/A | $521K |
| Operating Income | -$808K-0.4% | -$805K | N/A | -$715K+4.4% | -$748K+28.0% | -$1.0M | N/A | -$951K |
| Net Income | -$774K-1.0% | -$766K | N/A | -$667K+10.0% | -$741K+27.2% | -$1.0M | N/A | -$941K |
| EPS (Diluted) | -$0.430.0% | -$0.43-207.1% | -$0.14+62.2% | -$0.37 | -$1.33 | -$1.92-9700.0% | $0.02+100.1% | -$14.21 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
BBLGW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.4M-10.9% | $5.0M-14.1% | $5.8M-8.7% | $6.4M-9.3% | $7.0M+121.4% | $3.2M-18.1% | $3.9M-5.0% | $4.1M |
| Current Assets | $4.4M-10.9% | $5.0M-14.1% | $5.8M-8.7% | $6.4M-9.3% | $7.0M+121.4% | $3.2M-18.1% | $3.9M-5.0% | $4.1M |
| Cash & Equivalents | $4.0M-11.0% | $4.5M-15.1% | $5.3M-11.8% | $6.0M-8.9% | $6.6M+141.8% | $2.7M-17.4% | $3.3M-6.8% | $3.6M |
| Total Liabilities | $512K+65.5% | $309K-26.1% | $419K+25.2% | $334K-17.7% | $406K+61.7% | $251K-33.5% | $378K+38.2% | $273K |
| Current Liabilities | $512K+65.5% | $309K-26.1% | $419K+25.2% | $334K-17.7% | $406K+61.7% | $251K-33.5% | $378K+38.2% | $273K |
| Total Equity | $3.9M-16.0% | $4.7M-13.2% | $5.4M-10.6% | $6.0M-8.8% | $6.6M+126.6% | $2.9M-16.4% | $3.5M-8.1% | $3.8M |
| Retained Earnings | -$89.7M-0.9% | -$88.9M-0.9% | -$88.1M-0.8% | -$87.4M-0.8% | -$86.8M-0.9% | -$86.0M-1.2% | -$85.0M-1.8% | -$83.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BBLGW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$518K+35.5% | -$804K-12.5% | -$715K-20.9% | -$591K-28.9% | -$459K+50.5% | -$926K+31.6% | -$1.4M-136.6% | -$572K |
| Financing Cash Flow | N/A | N/A | $0 | $0-100.0% | $4.4M+1152.4% | $348K-68.8% | $1.1M-38.4% | $1.8M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
BBLGW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -19.7%-3.3pp | -16.4% | N/A | -11.1%+0.2pp | -11.2%+23.7pp | -34.9% | N/A | -24.8% |
| Return on Assets | -17.4%-2.1pp | -15.4% | N/A | -10.5%+0.1pp | -10.6%+21.6pp | -32.2% | N/A | -23.1% |
| Current Ratio | 8.67-7.4x | 16.09+2.2x | 13.85-5.2x | 19.00+1.8x | 17.24+4.7x | 12.59+2.4x | 10.22-4.6x | 14.87 |
| Debt-to-Equity | 0.13+0.1x | 0.070.0x | 0.080.0x | 0.060.0x | 0.060.0x | 0.090.0x | 0.110.0x | 0.07 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Bone Biologics Ranks
Frequently Asked Questions
Is Bone Biologics profitable?
No, Bone Biologics (BBLGW) reported a net income of -$3.1M in fiscal year 2025.
What is Bone Biologics's return on equity (ROE)?
Bone Biologics (BBLGW) has a return on equity of -57.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bone Biologics's operating cash flow?
Bone Biologics (BBLGW) recorded an outflow of $2.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bone Biologics's total assets?
Bone Biologics (BBLGW) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Bone Biologics spend on research and development?
Bone Biologics (BBLGW) invested $1.1M in research and development during fiscal year 2025.
What is Bone Biologics's current ratio?
Bone Biologics (BBLGW) had a current ratio of 13.85 as of fiscal year 2025, which is generally considered healthy.
What is Bone Biologics's debt-to-equity ratio?
Bone Biologics (BBLGW) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bone Biologics's return on assets (ROA)?
Bone Biologics (BBLGW) had a return on assets of -53.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bone Biologics's Piotroski F-Score?
Bone Biologics (BBLGW) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bone Biologics's earnings high quality?
Bone Biologics (BBLGW) reported a net loss of $3.1M while operations used $2.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.